InvestorPresenta,onASX:OSPDecember2017

Companyhighlights

2

•  12thconsecu,vequarterofgrowthachievedsincefirstrevenues

•  Valuableandinnova>veproductpor@oliowithFDA-cleared,TGA-clearedandCE-Markedproducts

•  DyeVertistheonlydevicewithanFDAclearedclaimfordyereduc,onwithoutcompromisedimagequality

•  Productswithdyeminimiza>onandmonitoringendorsedbycardiologysocietyguidelines

•  US$1.8billiontotaladdressablemarketforDyeVertandnewproductDyeTect

•  Top>erBoardandmanagementteam,investedinOsprey’ssuccess

•  Strongbalancesheetposi>onedforgrowth

Ospreyisaccelera,ngcommercialisa,onofitsproducts

Recenttradingupdate

3

Osprey’stradinghasreturnedtonormalfollowingimpactofHurricanesHarveyandIrma

ImpactofHurricanesonUS ImpactonOsprey

•  InlateAugust2017,Texas,GeorgiaandFloridawereaffectedbyHurricanesHarveyandIrma

•  HarveyandIrmaweretwoofthecostliestUSnaturaldisastersonrecordwithcombineddamageofgreaterthanUS$200billion

“Stormrelateddisrup0onsandrebuildingwillaffecteconomicac0vityintheneartermbutpastexperiencesuggeststhatthestormsareunlikelytomateriallyalterthecourseofthena0onaleconomyoverthemediumterm.”–USFederalReserve

•  Achieved12thconsecu>vequarterofgrowthdespitesubstan>aldisrup>ontokeysalesterritoriesfromthehurricanes

•  Con>nuedtomaintainstrongleadingindicatorsforfuturegrowth,with52hospitalsnowintheevalua>on-to-purchasephase

“DespitethesevereimpactofHurricanesHarveyandIrmaonSouthernTexas,FloridaandGeorgia,wewereencouragedbycon0nuedstronggrowthinunaffectedterritoriesandpleasedthatouroverallsalesgrowthwasposi0ve.Wehaveseenastrongstarttothecurrentquarterandlookforwardtoresumingourstronggrowthtrajectory.”-MikeMcCormick(OspreyPresidentandCEO)

Ospreyisdedicatedtoprotec,ngkidneys

4

Ospreyspecialisesinthecommercialisa,onofproprietarytechnologiesdesignedtoprotectkidneysfromtheharmfuleffectsofdye

Commonlyperformedimagingproceduresfortheheartandlegsrequiretheinjec,onofx-raydye,whichisthenclearedbythekidney

•  Theharmfuleffectsofdyecancausedamagetopa>ents’kidneys,knownasContrastInducedAcuteKidneyDamage(CI-AKI)

•  DyeVertandDyeVertPlusareproprietarydyereduc>onandmonitoringtechnologiesdesignedtoprotectthekidneysofpa>entswithchronickidneydisease,whoaremostatriskofCI-AKI

Pa,entImpactFromCI-AKI

CI-AKIisagrowingproblemassociatedwithpoorpa,entoutcomesaVercoronaryangiographyorinterven,on

Tsai TT, Patel UD, Chang TI et al. Contemporary Incidence, Predictors, and Outcomes of Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions: Insights from the NCDR Cath-PCI Registry. J Am Coll Cardiol Intv 2014;7:1-9.

AKI incidence: population incidence of acute kidney injury among cardiac cath. and PCI patients in the United States from 2001 to 2011. AKI indicates acute kidney injury. Brown J et al. J Am Heart Assoc. 2016;5:e002739.

5

HospitalImpactFromCI-AKI

Hospitalcostsincreaseforpa,entswithCI-AKIasmostprocedure-relatedpooroutcomesaretheresponsibilityofthehospital

6

1SubramanianS,etal.EconomicBurdenofCIN:Implica>onsforPreven>onStrategies.JournalofMedicalEconomics.2007;10:119-134.1PfunterA,etal.AgencyforHealthcareResearchandQualitySta>s>calBrief#168.December2013.hips://www.hcup-us.ahrq.gov/reports/statbriefs/sb168-Hospital-Costs-United-States-2011.pdf2CenterofMedicareandMedicaidServicesWebsite:hip://www.cms.gov/Medicare-Fee-for-Service-Payment/AcuteInpa>entPPS/Readmissions-Reduc>onpProgram.html2AmericanHospitalAssocia>onFactsheet:HospitalReadmissionReduc>onProgram.April14,2014.hip://www.aha.org/content/13/fs-readmissions.pdf3AmericanCollegeofCardiologyCMSReleasesProposed2018MedicareQPPRulehip://www.acc.org/latest-in-cardiology/ar>cles/2017/06/20/17/40/cms-releases-proposed-2018-medicare-qpp-rule

1.Increasedlengthofstay1

2.Increased30-dayreadmissions2

3.Increasedbundledpaymentrisk3

Osprey’ssolu,on:DyeVertPlusSystem

7

Easytosetup,anddoesnotdisruptpa,entflowandrequiresnochangefromstandardphysiciantechnique

With Osprey dye reduction

Without Osprey dye reduction

Compellingeconomicargument

8

CI-AKIincreaseshospitalcoststhroughincreasedlengthofstayand30-dayreadmissions–Osprey’sDyeVerthelpsmi,gatetheserisks

•  CI-AKIpa>entsaverage4daysofextendedhospitaliza>on1-3

•  Addi>onalhospitaliza>oncosts~$12,000foreachCI-AKIpa>ent4

•  Extendedhospitaliza>onnega>velyimpactshospitalandphysicianqualityscores(highlyrelevantforhospitalinUShealthsystem)

1PfunterA,etal.AgencyforHealthcareResearchandQualitySta>s>calBrief#168.December2013.hips://www.hcup-us.ahrq.gov/reports/statbriefs/sb168-Hospital-Costs-United-States-2011.pdf.2ChertowGM,etal.AcuteKidneyInjury,Mortality,LengthofStay,andCostsinHospitalizedPa>ents.JAMSocNephrol.2005,16:3365-3370.3LiangosO,etal.EconomicBurdenofCIN:Implica>onsforPreven>onStrategies.JournalofMedicalEconomics.2007;10:119-134.4SubramanianS,etal.EconomicBurdenofCIN:Implica>onsforPreven>onStrategies.JournalofMedicalEconomics.2007;10:119-134.5KoulouridisI,etal.Hospital-AcquiredAcuteKidneyInjuryandHospitalReadmissions:ACohortStudy.AmKidneyDis.2015;65(2):275-282.

15xCI-AKIpa,entsare15,mesmorelikelytobehospitalizedover4days

37%CI-AKIpa,entshavea37%increasein30-dayreadmissions

5

ProvenCustomerAdop,on

9

Keycustomeradop,onmetricsshowstrongproductperformancetoaddressunmetclinicalneedforCI-AKIreduc,on

Quarterlyunitsalesgrowth

TotalhospitalspurchasingDyeVert

Strongpipelineofhospitals

178%unitsalesgrowthinQ32017,ascomparedtoQ32016

144%increaseinnewhospitalspurchasingyearoveryear

52hospitalsatendofQ32017inthesample-to-purchaseprocess

1

2

3

Quarterlyproductunitsalessinceincep,on

0

200

400

600

800

1,000

1,200

1,400

4Q141Q152Q153Q154Q151Q162Q163Q164Q161Q172Q173Q17

AVERTsales DyeVertsales

Focusedcommercialisa,onapproach

10

Ospreyfollowsatwo-stepsalesprocessinallterritories

Sample-to-purchase(approx.3-4months)•  SalesrepsdirectlyapproachkeyphysicianstosampleDyeVert•  90%ofphysiciansapproachedprogresstoevalua>ngtheproduct•  Thesephysiciansthensupporttheproduct’spurchasewiththe

hospitalValua>onAssessmentCommiiee

Increasingpenetra>onwithinhospitals•  Onceahospitalisapprovedtopurchase,thefocusshiqsto

expandingtheproduct’sreachtoallphysicians•  Increasedpenetra>onwithinpurchasinghospitalsensures

thatallpa>entswithpoorkidneyfunc>onarecoveredbyDyeVert

01

02

Pillarsofsalesgrowthstrategy

11

Aggressivecommercializa,onstrategyfocusesonnewsalesrepresenta,vesandincreasingawarenessabouttheimportanceofkidneyprotec,on

SalesterritoryexpansionFocusonaddingnewhighlyexperiencedsalesrepsinterritorieswiththehighestratesofpoorkidneyfunc>on

Podiumpresenta,onsandphysicianadvocatesFocusonkeyopinionleadingphysicianswhoadvocateforthebenefitsofOsprey’sproductsatkeyindustryconferences

Marke,ngkidneyprotec,onFocusonmarke>ngthebenefitsofOsprey’sproductsinprotec>ngpa>ents’kidneysandtheirabilitytohelphospitalsadheretona>onalguidelinesarounddyesavings

ImprovementsandnewtechnologiesandplabormsConstantinnova>onfocusedonimprovingpa>entoutcomesandreducinghospitalcosts.

Salesterritories

1.  Shadingonthemapreflectspopula>ondensity

12

CA-South

TX-EastTX-South

Southeast

FL-Central

Carolinians

TX-North

FL-South

CA-North

St.Louis

Chicago LongIsland/JerseyShore

Cincinna,

Arizona/LasVegas

CT/NJ

FL-Tampa

Minnesota

Existing Sales Territories 18

Next Planned Sales Territories 3

Existing Clinical Specialist 5

Pihsburgh

MI

LouisianaArkansas

Next Planned Clinical’s 2

Colorado/Utah

Highqualitysalesrepsstrategicallyposi,onedinareaswithhigherinstancesofkidneydamage,withplanstogrowsaleshires

Marke,ngkidneyprotec,on

13

“BeKindtoKidneys”campaignisdrivingadop,onoftheDyeVertSystembyincreasingawarenessforthena,onaldyesavingsguidelines

Theproblem Theguidelines Osprey’sproducts

Onlyproductclearedforcontrastreduc>on

•  Screenforrisk

•  Increasehydra>on

•  Minimizecontrast

Marke,nghowwesolveAKI

14

Podiumpresenta,ons

Ospreyiscommihedtosuppor,ngkeyscien,ficconferencesandresearch

15

AmericanCollegeofCardiology(ACC)Dr.PrasadpresentedonDyeVertPlusatInnova>onSymposiuminMarch2017

CardioRenalConnec,onsTwopodiumpresenta>onsonDyeVertPlusinApril2017

EmoryPrac,calInterven,onCourse(EPIC)Mee>ngsponsorwithfocusedmessageonDyeVertPlus

SocietyforCardiovascularAngiographyandInterven,ons(SCAI)Threepodiumpresenta>onsonDyeVertatbreakfastsymposium

ComplexCardiovascularCatheterTherapeu,cConference(C3)Dr.RichardHauserpresentedonAKIreduc>onstrategies,includingDyeVert

Na,onalCardiovascularDataRegistry(NCDR)Onlymedicaldeviceexhibi>ng,focusedmessage“BeKindtoKidneys”

TranscatheterCardiovascularTherapeu,cs(TCT)Co-sponsoredluncheonandCI-AKISymposiumwithmul>pleDyeVertpresenta>ons

Clinicalresearch

Post-approvalclinicalresearchac,vi,es

16

Ospreysponsoredtrials•  DyeVertPlusmul>centertrial,primaryendpointdyesavings,secondaryadverseeventstoincludeCI-AKI

Physicianini,atedQualityImprovementtrials•  AHA/ACCguidelinesplusDyeTect™orDyeVertPlus•  Datacollec>onincludesACCNCDRCath-PCIregistry•  OutcomesincludeAKIreduc>onanddyereduc>on

Physicianini,atedhighriskpa,entpopula,ontrials•  CTO-primaryendpointcontrastvolumevs.ProgressCTORegistry•  STEMI-primaryendpointcontrastvolumesavings

17

Latestresearchpublishedinleadingmedicaljournalsupportsgreateradop,onofOsprey’sproducts

Posi,vedatahighlysuppor,veofOsprey’sproductswasrecentlypublishedintheJournaloftheAmericanMedicalAssocia,on(JAMA)

•  JAMAisthemostwidelycirculatedmedicaljournalglobally,publishedsince1883

•  JAMA’srecentpublica>onanalyseddatafromNCDRdatabase

ü Concludedthatdyereduc>onwasnecessarytominimizeAKI1

ü DyeVertistheonlydevicewithanFDAclearedclaimfordyereduc>onwithoutcompromisedimagequality

Researchfindingsaresuppor,veoffutureadop,onofDyeVertandDyeVertPlus,theonlyproductswithFDAclearancefordyereduc,on

“AKIratesvarygreatlyamongphysicians,whoalsovarymarkedlyintheiruseof

contrastanddonotusesubstan>allylesscontrastinpa>entswithhigherriskforAKI.

ThesefindingssuggestanimportantopportunitytoreduceAKIbyreducingthe

varia,onincontrastvolumesacrossphysiciansandloweringitsuseinhigher-risk

pa,ents.”1

DrAmitAmin

1.  “Varia>oninContrastVolumewithAcuteKidneyInjuryinPa>entsUndergoingPercutaneousCoronaryInterven>on”–DrAmitAmin,JournalofAmericanMedicalAssocia0onCardiology,publishedonline5July2017

Recentsuppor,veresearch

18

Newproductpipelineexpandsmarketpoten,alforkidneyprotec,on

ApprovedbykeyregulatorsinUSandEU

LeveragestechnologyfromDyeVertPlus

Increasesaddressablemarketby40%

Newproductpipeline

CEMarkexpected2Q,FDA4Q2017

Offersdyesavingsforpowerusers

Approximately25%ofUSangiographymarket

Inmarketwithini-allaunchphase,receivingvaluableclinicianfeedback

Osprey’saddressablemarketnow$1.8bn

19

LaunchofDyeTectincreasesOsprey’saddressablemarketby40%toUS$1.8billionbyaddinganaddi,onal3.5millionrelevantprocedures

DyeVertPlusmarketopportunityof3.2millionproceduresperyearintheUSAandWesternEU‒  CKD:1.3millionproceduresperyear‒  Diabetes:1.0millionproceduresperyear‒  STEMI:440Kproceduresperyear‒  Peripheral:450Kproceduresperyear

DyeTectmarketopportunityof3.5millionproceduresperyearintheUSAandWesternEU‒  Coronary:3.1millionproceduresperyear‒  Peripheral:476Kproceduresperyear

AveragesellingpriceofDyeVertisUS$355ExpectedlistpriceofDyeTectisUS$149

Totalmarketopportunity$1.8billion

Keydriversofshareholdervalue

20

Ospreyremainsfirmlyfocusedonsalestodriveshareholderreturns

SALESGROWTHGrowsalesteamandterritories

•  OngoingquarteronquartersalesgrowthofDyeVertisexpectedtocon>nuewithincreasingawarenessandagrowingsalesteam

•  PilotsalesterritoryunderwayinGermanyandJapan

ECONOMICSCapitalizeonnewlegisla0on

•  Takeadvantageofmandatorydyesavingsguidelines•  Capitaliseontheshiqofhospital/physicianpaymentsbasedon

“procedurevolume”to“improvingquality”

•  FirstinHumanExperienceDyeVertPlus,pendingpublica0oninJIC•  DyeVertRCT,submissioncompletedexpectpublica0on4Q2017•  Contrast-InducedAKI:Preven>veMeasuresthatWork.TCT2017•  FirstinHumanExperience,DyeTect.Submissionplanned

PODIUMScien0ficpresenta0ons

R&DDevelopmentofR&DporYolio

•  Powerinjector-compa,bleDyeVertindevelopment•  WorkingwithkeyPhysiciansonspeciallydesignedDyeVertPlusthat

willbeop>mizedforChronicTotalOcclusionsandSTEMI

Companyoverview

21

Osprey’sposi,vesharepricemomentumissupportedbystrongsalesgrowthandreflec,veofitsexci,ngpipelineoffuturecustomers

Topshareholders CDIs %

BrandonCapitalPartners 91.4m 26.9%

CMCapitalVT 34.0m 10.0%

JCPInvestmentPartners 17.4m 5.1%

Financialinforma,on

Shareprice(1-Dec-17) A$0.43

52weeklow/high A$0.34/A$0.51

Numberofshares(m) 339.4

Marketcapitalisa,on A$145.9m

Cash(30-Sep-17) US$36.1m/A$27.3m

Debt(30-Sep-17) Nodebt

Enterprisevalue A$118.6m

•  Inaddi>on,Kine>cInvestmentPartnersLtdhasinterestsinapproximately7%oftheissuedcapitalofOsprey

Note:Greyshadingrepresentssubstan>alholdingsassociatedwithOspreyBoardmembers,ChrisNaveandAndyJane

Note:AssumesAUDUSDexchangerateof0.75

SharepriceperformanceAcps Volume

-

0.2

0.4

0.7

0.9

1.1

1.3

1.5

1.8

2.0

15

20

25

30

35

40

45

50

55

Dec-16 Feb-17 Apr-17 Jun-17 Aug-17 Oct-17 Dec-17

Volume OSPcloseprice

This presenta>on has been prepared by Osprey Medical, Inc. (“Osprey” or the “Company”) for the sole purpose of providing general and backgroundinforma>ononOsprey.Thispresenta>ondoesnotcontainallinforma>onnecessarytomakeaninvestmentdecision.

This presenta>on does not cons>tute an offer, invita>on, solicita>on or recommenda>on by any person to sell or apply for securi>es in Osprey in anyjurisdic>on,andnoneofthispresenta>ondocumentoritscontentsshallformthebasisofanycontractorcommitment.Thispresenta>onisnotintendedtocons>tutelegal,taxoraccoun>ngadviceoropinion,orfinancialproductadviceandshouldnotberelieduponasarepresenta>onofanymaierthatapersonshouldconsiderinevalua>ngOsprey. Youmustnotrelyonthepresenta>onprovidedbutmakeyourownindependentassessmentofthepresenta>onandseekandrelyuponyourownindependenttaxa>on,legal,financialorotherprofessionaladviceinrela>ontothepresenta>on.Thispresenta>ondoesnottakeintoaccountanyourinvestmentobjec>ves,taxa>onsitua>on,financialsitua>onorneeds.Ospreyisnotlicensedtoprovidefinancialproductadviceinrespectofitssecuri>esoranyotherfinancialproducts.Coolingoffrightsdonotapplytotheacquisi>onofOspreysecuri>es.

None of Osprey, its officers, directors, employees and agents, nor any other personmakes any representa>on orwarranty, express or implied, as to, orendorsementof,Osprey,theaccuracyorcompletenessofany informa>on,statementsorrepresenta>onscontained inthispresenta>onandnoneofthemacceptsanyresponsibilityorliabilityforanyerrorsoromissionsinthispresenta>onwhatsoever.

Theinforma>oninthispresenta>onissubjecttochangewithoutno>ceandOspreydoesnothaveanyresponsibilityorobliga>ontoinformyouofanymaierarisingorcomingto theirno>ce,aqer thedateof thispresenta>on,whichmayaffectanymaier referredto in thispresenta>on. Thedistribu>onof thispresenta>onmayberestrictedbylawandyoushouldobserveanysuchrestric>ons.

Thispresenta>oncontainscertainforwardlookingstatementswhichinvolveknownandunknownrisks,uncertain>es,andotherfactorswhichmaycausetheactualresultsorperformanceofOspreytobemateriallydifferentfromtheresultsorperformanceexpressedorimpliedbysuchforwardlookingstatements.Past performance is not necessarily a guide to future performance and no representa>on or warranty is made as to the likelihood of achievement orreasonablenessofanyforwardlookingstatementsorotherforecast.

Allfigures in thepresenta>onareA$ thousandsonaconstantcurrencybasisbasedonanexchange ratesofA$1:US$0.75unless statedotherwiseandallmarketsharesarees>matesonly.Thepro-formahistoricalfinancialinforma>onincludedinthispresenta>ondoesnotpurporttobeincompliancewithAr>cle11ofRegula>onS-Xoftherulesandregula>onsoftheUSSecuri>esandExchangeCommission.Thispresenta>onmaycontaincertainfinancialdatathatis"non-GAAPfinancialmeasures"underRegula>onGundertheU.S.Securi>esExchangeActof1934,asamended.Thedisclosureofsuchnon-GAAPfinancialmeasuresinthemannerincludedinthispresenta>onwouldnotbepermissibleinaregistra>onstatementundertheSecuri>esAct.Thesenon-GAAPfinancialmeasuresdonothaveastandardisedmeaningprescribedbyAIFRSand, therefore,maynotbecomparabletosimilarly>tledmeasurespresentedbyotheren>>es,norshould theybeconstruedasanalterna>vetootherfinancialmeasuresdetermined inaccordancewithAIFRS.Althoughwebelieve thesenon-GAAPfinancialmeasuresprovideusefulinforma>ontousersinmeasuringthefinancialperformanceandcondi>onofourbusinessforthereasonssetoutinthispresenta>on,youarecau>onednottoplacedunduerelianceonanynon-GAAPfinancialmeasuresandra>onsincludedinthispresenta>on.

DyeVert™,DyeVert Plusand DyeTect SystemsRegulatory Status:Europe – CEMark obtained;Australia – TGA approval obtained;United States – 510(k)cleared.

IC0012Rev.A

Disclaimer

22